GSK (then known as SmithKline Beecham) knew in a 1999 trial that Avandia, the drug undergoing scrutiny on its fate in the pharma marketplace today, posed a signficant cardiac risk when compared to its major competitor Actos — and it purposefully covered up that information. This, according to a report obtained by the NYT.

The reports … say that if every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month because Avandia can hurt the heart.

GSK has always stuck to its guns in defending its assertions that statements like that are based upon faulty safety information gleaned from major trials casting the drug in a negative light — like the well-known RECORD trial, which found that the overall risk of cardiovascular death of Avandia was not statistically significant. That meta-analysis was commissioned by GSK at the request of the FDA.

This is just the latest revelation in a very public battle over a Pharma company’s credibility in the healthcare marketplace and the validity of new information from a Senate investigation into that company’s handling of the trial results. Implications on who controls subsequent drug safety and treatment data years after a drug’s initial availability and what it means for the welfare of the public taking the drug versus pharma profits from the sale of the drug should be weighing greatly on the FDA panel making the decision on the drug’s ultimate fate. | LINK

Related Posts Within Doctor Pundit:

1. FDA Considers Ending Troubled GSK Drug’s Involvement in Safety Study Add yet another blow to GSK’s once-blockbuster diabetes drug, Avandia...
2. Diabetes Drug Once Again under Scrutiny A couple of weeks before the FDA meets to discuss...
3. FDA to Decide Fate of Diabetes Drug This Week It’s official. The FDA will convene this Tuesday (13) to...
4. FDA Discussions on Avandia Enter 2nd Day As the debate over Avandia enters its second day, more...
5. FDA: Keep Avandia on Market, Impose Ponderous Restrictions on Use The FDA has announced today Avandia’s official indication. After months...